Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12632467 | 0.93 | ALDH1A1 (0.57) | ALDH1A1EPHX2NR1H4ENPP2LMNA | |
| SCHEMBL548599 | 0.82 | ALDH1A1 (0.67) | ALDH1A1LMNAGAAHSD11B1MAPT | |
| SCHEMBL9360098 | 0.82 | ALDH1A1 (0.67) | ALDH1A1LMNAGAAHSD11B1MAPT | |
| SCHEMBL27438701 | 0.81 | ENPP2 (0.48) | ALDH1A1EPHX2NR1H4ENPP2PTGS2 | |
| SCHEMBL14016158 | 0.81 | ENPP2 (0.48) | ALDH1A1EPHX2NR1H4ENPP2PTGS2 | |
| SCHEMBL23893664 | 0.81 | ENPP2 (0.54) | ALDH1A1EPHX2NR1H4ENPP2HSD11B1 | |
| SCHEMBL28359568 | 0.81 | PTGS2 (0.51) | ALDH1A1EPHX2NR1H4ENPP2HSD11B1 | |
| SCHEMBL12163508 | 0.81 | ALDH1A1 (0.59) | ALDH1A1EPHX2NR1H4LMNAGAA | |
| SCHEMBL13239460 | 0.81 | ENPP2 (0.54) | ALDH1A1EPHX2NR1H4ENPP2HSD11B1 | |
| SCHEMBL14349351 | 0.81 | ENPP2 (0.48) | ALDH1A1EPHX2NR1H4ENPP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 515 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075051-A1 | PROCESS FOR RECYCLING CONTAMINATED POLYMERS | ARKEMA FRANCE (FR) | 2025-03-06 | — | — | US | claimed |
| EP-4457275-A1 | PROCESS FOR RECYCLING CONTAMINATED POLYMERS | ARKEMA FRANCE (FR) | 2024-11-06 | — | — | EP | claimed |
| WO-2023126441-A1 | PROCESS FOR RECYCLING CONTAMINATED POLYMERS | ARKEMA FRANCE (FR) | 2023-07-06 | — | — | WO | claimed |
| EP-4206267-A1 | PROCESS FOR RECYCLING CONTAMINATED POLYMERS | ARKEMA FRANCE (FR) | 2023-07-05 | — | — | EP | claimed |
| US-20250075051-A1 | PROCESS FOR RECYCLING CONTAMINATED POLYMERS | ARKEMA FRANCE (FR) | 2025-03-06 | — | — | US | disclosed |
| EP-4457275-A1 | PROCESS FOR RECYCLING CONTAMINATED POLYMERS | ARKEMA FRANCE (FR) | 2024-11-06 | — | — | EP | disclosed |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| CN-1273865-C | Method for forming pattern | CLARIANT INT LTD (JP) | 2006-09-06 | — | — | CN | disclosed |
| CN-1811600-A | Pattern forming method | AZ ELECTRONIC MATERIAL CO LTD (JP) | 2006-08-02 | — | — | CN | disclosed |
| CN-1241064-C | Chemically amplified resist composition | AZ ELECTRONIC MATERIALS JAPAN (JP) | 2006-02-08 | — | — | CN | disclosed |
| CN-1263611-A | Method for forming pattern | CLARIANT INT LTD (CH) | 2000-08-16 | — | — | CN | disclosed |
| CN-1263612-A | Chemically amplified resist composition | CLARIANT INT LTD (CH) | 2000-08-16 | — | — | CN | disclosed |
| US-3976672-A | INSECTICIDE | UNIROYAL INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | ALDH1A1 3666/4885EPHX2 3834/4885NR1H4 1693/4885 |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | ALDH1A1 2107/4885EPHX2 597/4885NR1H4 1426/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | ALDH1A1 3140/4885EPHX2 1702/4885NR1H4 2/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | ALDH1A1 2178/4885EPHX2 671/4885NR1H4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.